657830login-checkFDA OKs Cell Therapy to Lower Infection Risk After Stem Cell Transplant |
— Omidubicel reduced infections in blood cancer patients from 60% to 39% at 100 days posttransplant
By Ian Ingram
The FDA approved omidubicel (Omisirge) opens in a new tab or window to reduce the risk for infections in hematologic cancer patients undergoing stem cell transplant, the agency announced on Monday.
Omidubicel is designed to speed up neutrophil recovery and is indicated for patients ages 12 and up planning to undergo umbilical cord blood transplantation (UCBT) following a myeloablative conditioning regimen, which can impair the immune system. Read more in MedPage Today.
657830login-checkFDA OKs Cell Therapy to Lower Infection Risk After Stem Cell Transplant |